News Hub | News Direct

NextFerm Technologies Announces First Commercial Production of ProteVin™, Its Vegan Protein

NextFerm Technologies Ltd.

This marks the achievement of first out of five strategic milestones set by the company for 2022 The Company expects to supply first orders of ProteVin™ in the coming weeks; Company is currently in dialogues with food and dietary supplement global companies for the integration of ProteVin™ in their alternative product lines NextFerm Technologies Ltd. (TASE:NXFR), a food-tech company developing ProteVin™, a vegan, yeast-based, non-GMO protein alternative and other innovative yeast-based nutrients, today announced the end of commissioning period of the commercial facility in Canada and first commercial production of ProteVin™, Its Vegan Protein. The operation of first commercial facility following commissioning and successful production of first batches mark the achievement of the first milestone out of five milestones set by the company for 2022. The Company continues to progress towards achieving the rest of its objectives for 2022, including delivery of initial orders received, increasing market demand for ProteVin™, receipt of additional purchase orders and expanding penetration into the global food market. In parallel, increasing commercial production capacity to an industrial scale of hundreds of tons per year in 2023. Boaz Noy, Chief Executive Officer of NextFerm, said: "Initiating commercial production of Protevin™, marks a significant milestone for the company moving forward from R&D phase to commercial phase. Achieving this milestone allows us to progress towards achieving the additional milestones we set for 2022. In the coming weeks, we expect to supply first orders of ProteVin™ for customers in the field of sports nutrition formulas." "The alternative protein market is the main growth engine of the global food industry, and we expect high demands for Protevin™, as a proprietary vegan protein source for a variety of alternative food products, with a rich amino acid composition similar to animal-based protein, highest digestibility factor (PDCAST=1) and neutral flavor." About NextFerm Technologies NextFerm Technologies, traded on the Tel Aviv Stock Exchange (TASE: NXFR) is a food-tech company engaged in the research, development, manufacturing and marketing of innovative, functional and vegan yeast-derived, non-GMO protein alternatives for various applications in the food and food supplement markets and the growing market for animal-derived protein alternatives. NextFerm's flagship product is ProteVin™, a vegan, yeast-derived protein alternative with nutritional value that is similar to animal-derived protein (Amino acid profile BCAA=21%, Leucine=9%, EAA=53% and high digestibility PDCAAS=1) and a neutral flavor, with no aftertastes that are typical of plant-based protein. ProteVin™ is designed for a variety of categories in the alternative protein market, which is estimated at USD 20 billion in terms of final products and at USD 5 billion in terms of raw materials with an annual growth rate of above 20%, including milk and dairy substitutes, meat substitutes and additional categories such as infant nutrition, adult nutrition, and sports nutrition. NextFerm has just commercialized the product as reported. Another product currently being sold is Astaferm®, an innovative astaxanthin-based antioxidant derived from yeast that has been sold in the US since the end of 2020 through well-established and leading brands in the food supplement market in the US. In July 2021, the Company received Regulatory marketing approval in Canada. The company has additional products which have been licensed to Lallemand, a global giant focused on yeast. For more information, visit the NextFerm website at: www.nextferm.com Legal Notice Regarding Forward-Looking Statements This announcement also includes forecasts, projections, assessments, estimates and other information which refer to future events and matters, the realization of which is uncertain and not exclusively under the Company’s control (forward-looking information). The main facts and data used to support this information are facts and data regarding the current position of the Company and its businesses (including the scope of sales and levels of profitability, manpower, commercial engagements and more), facts and data regarding the current global position of the Company’s operating segments (including industry-specific financial developments, environmental regulatory developments, the competitive environment, technological developments, the reinsurance market and more), and macro-economic facts and data (including the economic situation both in Israel and around the world, yields in the capital markets, social and state developments and more), all as known by the Company when publishing this announcement. The forward-looking information included above in this announcement is significantly based upon, in addition to the existing information held by the Company, on the Company’s current assessments and expectations of future developments vis-a-vis each one of the aforementioned parameters, and the interconnectedness of each one of these developments. The Company has no certainty that its forecasts and assessments will indeed eventuate, and the Company’s operating results may be materially different than the results assessed or implicit based on that set forth above, inter alia, as a result of a change in any of the aforementioned factors. Contact Details Investor and Media Contact Meirav Gomeh-Bauer +972 54-476-4979 meirav@bauerg.com Company Website https://www.nextferm.com/

June 20, 2022 10:05 AM Eastern Daylight Time

UK MEDTECH COMPANY TO HELP PROTECT US HEALTHCARE WORKERS AND US CITIZENS FROM 1 MILLON NEEDLESTICK INJURIES EACH YEAR

NeedleSmart

SAFETY INITIATIVE AND COMPLIANCE WILL SAVE AMERICAN HEALTHCARE INDUSTRY $1 BILLION British smart MedTech company NeedleSmart, which is pioneering disruptive technologies in the global healthcare sector, is expanding into the US healthcare market to protect American healthcare workers and patients from the rising tide of needlestick injuries (NSI). In the US alone, more than 1 Million NSI are reported each year, affecting frontline nurses, healthcare workers and patients. However, it is estimated that the more accurate figure may be five times that number, due to a culture of underreporting. Initially NeedleSmart will focus their efforts on helping the US healthcare system reduce Needlestick injuries (NSI). Pre Covid-19, NSI cost the US healthcare industry more than $1Bn each year. A cost built on treatments (both physical and mental), absenteeism, agency staff and in many cases law suits. Approximately 5.6 million healthcare workers in the US are at risk of occupational exposure to bloodborne pathogens via NSI or other sharps-related injuries, according to the Occupational Safety and Health Administration every year. Needlestick injuries are caused when a hypodermic needle accidentally punctures the skin. These injuries – which can happen at any time, however the NSI which carry the most significant risks are those that happen after exposure to the patient. The Centre for Disease Control and Prevention (CDC) estimates that at least 385,000 NSI occur each year to hospital-based healthcare workers, amounting to more than 1,000 NSI per day amongst hospital healthcare staff. Many more of those NSI also occur through emergency services, homecare and nursing homes. The CDC has also targeted the elimination of NSI as an agency priority, with both federal and state laws increasing enforcement of NSI injury prevention. Over 41% of NSI occur during use, with 41% occurring after use and before disposal, 15% occurring during and after disposal and 4% in other settings. NeedleSmart is working closely with lawmakers and Government agencies in the US to inform, advance and extend legislation that will protect healthcare workers and frontline staff. US based NeedleSmart Chief Operating Officer Michael Barron said: “Needlestick injuries were already a serious global problem pre Covid-19, with more than 3 million reported cases each year and rising. The introduction of a global vaccination program has added significantly to this with pandemic with NSI statistics yet to be made publicly available. The global supply and use of needles is at an all-time record, which means the risk of becoming injured by a NSI has also greatly increased. If we factor into this equation that hospitals, emergency services and healthcare staff are under even more pressure, facing longer shifts and suffering from burnout and chronic fatigue, this creates the perfect storm for an unprecedented increase and risk of NSI to US healthcare and frontline emergency services staff. While the reported figure of NSI in the US is 1 Million, it is believed that the actual figure could be considerably more due to a culture of under reporting NSI. With NeedleSmart, we can not only reduce and prevent NSI to key frontline healthcare staff, EMS personnel and patients, but we can increase staff efficiencies as we link our bespoke software solutions directly to the NeedleSmart Pro hardware and eliminate significant amounts of pre and post procedure administration and in-efficiency. Our audit and compliance software runs alongside the safe destruction technology to create a singular end to end workflow. NeedleSmart will significantly reduce post procedural PPNSI, directly targeting and reducing the $1Bn per year associated costs.” NeedleSmart, which has offices in Liverpool, England and Philadelphia USA, is already at the forefront of pioneering disruptive technologies with the British National Health Service (NHS) to prevent NSI to NHS healthcare workers and clinicians. It is also developing carbon reduction strategies in clinical waste disposal, as well as digitising vaccination programmes NeedleSmart has achieved FDA approval as a Class II medical device, making it the first UK company to achieve FDA 510(k) approval (Class II for Sharps Needle Destruction Device (NDD)). The NeedleSmart Pro device destroys a contaminated hypodermic needle in a sealed chamber in just 6 seconds, minimizing post-procedural NSI. The device heats the needle to 2372 degrees Fahrenheit, killing potentially harmful pathogens, viruses and bacteria adhering to the needle. Within seconds, the needle is compressed into a tiny ball and released from the NeedleSmart device as a safe sphere of metal at the tip of the syringe. The product can be seen here https://youtu.be/C968RkWtSi8 Aligned with this Needle Smart have set the ambitious goal of re-purposing this waste away from plastic sharps containers to a 96% recycled cardboard clinical waste container in the near future. NeedleSmart has developed a ground-breaking set of disruptive technologies in digital data and AI for medical and clinical records, healthcare worker safety and carbon reduction programs in clinical waste. To learn more about how the Needle Smart Pro works with the DVS system can be seen here https://www.youtube.com/watch?v=nIAzsMwyBDc NeedleSmart’s disruptive smart MedTech technologies are focussed on: Safety: The reduction and hopeful elimination of harmful post procedural NSI to US healthcare workers and patients Sustainability: Reducing the associated carbon footprint by up to 95% Efficiency: The digitalization of vaccination programs, medical treatments, clinical workflows and associated records. Cliff Kirby, NeedleSmart’s Global CEO, added “Not only is this the world’s first safe needle destruction technology that also has FDA 510 (k) approval as a Class II medical device (Sharps Needle Destruction Device (NDD)), but it is the only Smart MedTech to have a unique compliance and audit software each time a needle is used. “When used as part of a vaccination program, our system offers 30-50% increased efficiencies, providing unique compliance with a digital audit trail from the point of when the needle is unwrapped from its sterile packaging. This provides a full audit trail and compliance including, vaccination batch and manufacturer, the healthcare professional administering the vaccination, date, time and patient details – right through to the safe destruction of the needle. This firmly puts healthcare and EMS worker safety at the forefront.” ENDS For more information on Needle Smart, visit www.needlesmart.com www.digitalvaccination.com The Needle Smart process explainer https://youtu.be/C968RkWtSi8 The Needle Smart DVS explainer https://www.youtube.com/watch?v=nIAzsMwyBDc ABOUT NEEDLESMART NeedleSmart is a market-leading, British-patented needle destruction technology engineered in the UK, with offices in Knowsley and Pittsburgh, Pennsylvania. Its award-winning NeedleSmart Pro needle destruction device has achieved FDA approval as a Class II medical device, being the first UK company to achieve FDA 510(k) approval (Class II for Sharps Needle Destruction Device (NDD)). As well as contributing to the reduction of needlestick injuries and their consequential costs, the NeedleSmart process has the potential to reduce the cost and increase efficiency of used needle disposal. NeedleSmart’s innovative technology also offers the opportunity to move hypodermic needles, syringes and consumables associated with the injection/vaccination process, away from conventional sharps bins to a solution that allows recycling to become a possibility. NeedleSmart technology compresses the needle, significantly reducing the needle footprint leading to a minimum of 50% increase in needle count per sharps bin. After the unexpected Covid-19 pandemic and the mass vaccination program that followed, NeedleSmart's Digital Vaccination System (DVS) was created to support mass vaccination program, digitalizing the vaccination process, with every detail being automatically recorded in the cloud. DVS delivers a single solution that can coordinate every individual vaccination initiative into a single, coherent vaccination program. ABOUT MICHAEL BARRON CHIEF OPERATING OFFICER NEEDLESMART US Michael Barron has spent the last 30 years helping to build, scale, and lead high growth companies. As both an investor and executive, he has helped take several firms from inception to over $1Bn in assets. Michael has been featured in The Wall Street Journal and Investor’s Business Daily. He has been a regular guest on Bloomberg and CNBC. He is a board member at The Foreign Policy Research Institute and The Satell Institute. He a graduate of Villanova University. For more information https://www.linkedin.com/in/michaelbarron100/ MEDIA NOTICE NeedleSmart assets and images can be downloaded here https://we.tl/t-NQfuq4O9tr Contact Details NeedleSmart Gerard Franklin +44 7791 039636 gerard@i5media.co.uk Company Website https://www.needlesmart.com/

June 20, 2022 12:30 AM Eastern Daylight Time

Modern Weight Loss: What is Personalized Weight Care and Why You Should Try It

YourUpdateTV

According to the CDC, overweight and obesity are risk factors for many serious diseases and health conditions, including heart disease, stroke, type 2 diabetes, and some cancers, all of which are among the leading causes of preventable death. Recently Dr. Rekha Kumar from Found conducted a satellite media tour to talk about personalized weight loss and its benefits. A video accompanying this announcement is available at: https://youtu.be/ZEx5tcYjrlQ It is time we push back against harmful and outdated weight loss culture and start thinking about our overall health and weight care. A poll of 2,000 adults conducted by weight care platform, Found, revealed that 91% have tried at least one strategy for weight loss, with half revealing that they’ve tried 11 different methods of weight loss. According to that same poll: ● 25% of people even confessed to doing up to 16 diets in their lifetime! ● But only 15% described their weight loss experience as “rewarding” ● Respondents felt that losing weight required more sacrifice than having kids ( 33% )! ● 9 in 10 Americans have tried at least one weight loss strategy ● 33% wished they had access to prescription weight loss medications ● Almost four in five (79%) want to be healthier, not skinnier. Found is an evidence-based weight care solution that combines the best of modern medicine with personalized coaching and community. Centered around clinical care and lasting behavior change, Found provides its members with a comprehensive weight loss program that delivers long term, sustainable results. Found designs personalized treatments around every factor that makes people unique — from biology, medical history, mental health, existent lifestyle, goals, and more. Found’s members are supported by the best of consumer technology, and a team that includes doctors to prescribe safe medication, and coaches to guide them on nutrition, movement, sleep, and emotional health. They call this weight care. When diet and exercise don’t lead to effective weight loss, sometimes it’s our biology that’s holding us back. Much of how your body loses, gains, and maintains weight is predetermined by your biology. This means no amount of working out, eating healthy, or sheer willpower can sustain weight loss if your biology’s not set up for it. Medication can, which is why Found offers more medication options than any other program. Online weight loss means Found took the doctor's office out of the equation. The telehealth platform provides one-on-one medical, nutritional, and movement guidance from their experts, through an app that can be accessed anywhere and at any time. Found’s proprietary weight care platform is available via the App Store, Google Play, as well as on joinfound.com Rekha Kumar bio: Dr. Rekha Kumar is recognized as an international leader in the field of Obesity Medicine. She is Chief Medical Officer at weight care platform Found, as well as a practicing endocrinologist at an academic medical center in New York City. She also served as the former medical director of the American Board of Obesity Medicine. Dr. Kumar has lectured internationally on the topic of the medical assessment and treatment of obesity. She has published several papers and textbook chapters in her field and serves as an Associate Editor of the journal Obesity. She is frequently quoted in the media on topics ranging from the diabetes epidemic in the United States to discussing fad diets, exercise trends, and the complications of Covid-19 in patients with obesity. Dr. Kumar’s areas of expertise include the clinical assessment of patients obesity and metabolic syndrome, the effect of obesity on reproductive health and fertility, as well as thyroid disease. Dr. Kumar completed her undergraduate studies at Duke University then received her master’s degree in Physiology from Georgetown University. She continued on to receive her M.D. from New York Medical College and completed her residency training in Internal Medicine at the New York Presbyterian Hospital/Weill-Cornell Medical College. Dr. Kumar obtained her clinical fellowship in the combined Diabetes, Endocrinology, and Metabolism program at the Weill-Cornell Medical College/New York Presbyterian Hospital and the Memorial Sloan Kettering Cancer Center. Dr. Kumar has traveled abroad to India, China, and Tanzania to understand the scope of metabolic disease globally. She serves on the board of advisors of the Duke Global Health Institute. Dr. Kumar is Board Certified in Internal Medicine, Endocrinology, Diabetes, & Metabolism, and Obesity Medicine. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

June 17, 2022 10:00 AM Eastern Daylight Time

Video

All Things Bugs Achieves World First with US Patent for the use of Insects in Sustainable Food Production

All Things Bugs LLC

All Things Bugs LLC, the world’s leading innovator in the insect industry, today announced that it has received a US patent for its unique production method as it continues to develop pioneering products and research in the use of insects as sustainable food ingredients. US patent No. 11,337,451, issued on May 24, is the first US patent specifically focussed on insects as a food source, and it confirms All Things Bugs and its Founder and President Dr Aaron T Dossey as leaders in their field. The firm also has similar issued patents in Canada and Mexico. All Things Bugs is the world’s first insect-based food wholesaler, and, for the last decade, the company has developed products, services and research to promote insects as a viable alternative to traditional protein sources such as meat and dairy. All Things Bugs has focussed its efforts in four key areas: 1) Food product development 2) Insect processing and ingredients 3) Cutting-edge insect farming automation 4) Insect genomics and genetic engineering The patent provides recognition of the company’s spray-drying technology, and opens up new opportunities for the use of insects in global food production. All Things Bugs’ patented breakthrough involves the development of a new wet-grinding and drying technique that ensures edible insects can be ground into a fine powder. It is a process that works equally well with all insects including superworms, crickets, mealworms, grasshoppers, locusts, katydids, caterpillars or flies - emphasizing its versatility, and making it cost-effective to produce. Crucially, it is an environmentally-friendly and sustainable way to increase protein content across a whole range of foods. The end product is a super fine, light-colored powder with a neutral aroma and flavor, which can be blended with other ingredients to make numerous food and beverage products, such as pasta, baked goods, shakes, smoothies, meat alternatives, puffed extruded snacks, bars, cereals, tortillas, pet food / treats and many others. The growing need for a sustainable source of protein. Global food production has long relied on meat and dairy products as its main source of protein. This has had a devastating impact on the environment, with costly resources required to sustain it. Huge amounts of land are cleared every year for farming and agriculture, with water and feed production for cows, pigs, chickens, and even most plant-based proteins generating massive land and water use as well as vast energy consumption on a global scale. By comparison, insects make up the largest most diverse group of organisms on Earth. They are nature’s most sustainable protein source, yet very little has been done to utilize insects for people and for our planet. All Things Bugs takes a holistic view of the benefits insects can bring to humankind. As well as food production, the company is using genetic engineering technologies such as CRISPR to develop insects as a vehicle to manufacture non-food bioproducts for livestock and wild animal vaccines, antibiotics, biomaterials, enzymes and other applications. Its valuable work continues to benefit researchers, entrepreneurs, farmers, policymakers, and anyone interested in sustainable food production and the industrial use of insects. “This patent represents a historic opportunity for a shift in mindset towards an overall healthier planet,” said Dr Aaron T Dossey, Founder and President of All Things Bugs. “It proves the potential for turning insects into high quality ingredients efficiently and cost effectively. But, more than that, it is an ethical and sustainable solution to the ongoing challenge of scaling up food production without damaging life on earth in the process.” Dr Dossey published the first text book on the subject, Insects as Sustainable Food Ingredients, and is a leading authority in the field, providing valuable guidance on how to develop the insect-based agriculture, food, and biomaterial industries. For further information, contact info@allthingsbugs.com or visit https://allthingsbugs.com/ About All Things Bugs LLC All Things Bugs is the world’s leading innovator in the insect industry. Insects make up the largest most diverse group of organisms on Earth. They are the most sustainable protein source on the planet, beating out other animal and even plant protein sources. They also require far fewer resources such as land, water and feed to produce than animals and most plants, but very little has been done to utilize insects for the benefit of people and our planet. All Things Bugs develops sustainable insect-based solutions, technologies, and products for agriculture, food, and medicine. Contact Details All Things Bugs LLC Dr. Aaron T. Dossey +1 352-281-3643 info@allthingsbugs.com

June 15, 2022 07:00 AM Central Daylight Time

Image

ALDERHEY@NYWHERE™ CREATING A HOSPITAL OF THE FUTURE: “A HOSPITAL WITHOUT WALLS”

AlderHey Innovation / i5 Media

ALDER HEY LAUNCHES GROUND-BREAKING HYBRID DIGITAL HEALTH PLATFORM IN COLLABORATION WITH MICROSOFT AND MINDWAVE. “TODAY’S CHILD, TOMORROW’S HEALTHIER ADULT” Alder Hey Children’s NHS Foundation Trust, one of the world’s leading paediatric healthcare institutions, has today launched a ground-breaking digital platform that is set to revolutionise the way in which patient care is delivered to children and young people. The hybrid health platform AlderHey@nywhere™ is being championed as a “hospital of the future”, where patient and clinical care is delivered in a hybrid world, both physical and virtual, to create a “hospital without walls”. The interactive and immersive digital platform provides a hybrid point of access and patient care for families, children, young people and clinicians to manage, treat, educate and coordinate delivery of their healthcare. Most importantly, it will focus on preventative healthcare and will make patient care more accessible and personalised. https://www.alderheyinnovation.com/alderheyanywhere The technology was developed by Alder Hey Innovation in collaboration with Microsoft and Mindwave as a solution to addressing the finite capacity of hospital and community resources, including both physical space and workforce. This was also paired with an increased demand of accident and emergency admissions, long waiting times for outpatient appointments, and increasing lengths of stay. Alder Hey has a dedicated innovation centre within the hospital and campus, focused on using cutting-edge technologies and innovations to solve the real-world, day-to-day problems faced by children and young people. Alder Hey Innovation believes that by leveraging innovative health tech, digital platforms, data and AI, it can revolutionise the way healthcare is delivered to children and young people. It seeks to break down the traditional barriers for patients when accessing care and personal health information, as well as when receiving therapies and seeking education, creating a future of healthcare that is a “hospital without walls ” with the focus of care being the individual, taking a more personalised and tailored approach. Commenting on the launch of the new digital health platform, Managing Director of Alder Hey Innovation, Claire Liddy, said: “At the moment, healthcare is most often about treating people that are ill. What we want to do is to shift to a more preventative model of care that is individualised and tailored and that empowers children and young people to take ownership of their healthcare and treatment. There are so many different technologies out there now, including wearable technology and devices such as smartwatches that enable you to monitor your health at home. What we needed was a hybrid platform to bring it all together into one place so that families, children and young people could access it, alongside their clinicians at the hospital. “We think the AlderHey@nywhere™ platform will allow us to elevate the level and access to care for children and young people who tell us that they want to be empowered to understand and manage their own healthcare and treatment. It also allows us to move to a more preventative healthcare modelling, making healthcare more individual and personalised.” AlderHey@nywhere™ is a co-development with Microsoft and tech SME Mindwave. The collaboration came together to co-create a hybrid healthcare platform that will create a way of delivering healthcare for children and young people that is far more tailored to the individual, giving them better life chances. Claire Liddy added: “The Innovation Centre at Alder Hey Children’s hospital is a really special and unique place. It’s a dedicated team, all focussed on bringing new technology into healthcare for the benefit of children and young people. We work with a wide range of private sector partners, including tech giants, SMEs, entrepreneurs and universities, to co-invent new technologies and innovations. We have a different mindset and culture of innovation; we are able to move fast and think big, which allows our innovation path to accelerate much faster than the traditional pathways. We are able to fuse healthcare and tech innovation with industry. This fusion brings something special and unique, creating faster-paced technologies.” AlderHey@nywhere™ provides a unique digital platform that is designed with children young people and their families in mind, making it visually aesthetic, engaging and immersive, but also intuitive. At the same time, its dual purpose is engineered for clinicians to monitor, assess and optimise data and clinical workflow in the management and delivery of patient care. Mindwave – which has previously worked with Alder Hey to develop other tech platforms, including AlderPlay and mental health platform CYP As One™ – have been the lead developers on the visual interface of the portal, as well as the interconnectivity and operability of data. Founder and CEO, Kumar Jacob, said: “It has been a privilege to work with Alder Hey Innovation Centre and Microsoft to be responsible for the design and development of the user interface (UI) and user experience (UX) of AlderHey@nywhere™. Our role has been to ensure that the portal is visually appealing and immersive, making sure the experience that young people, children and their families have is engaging, enjoyable, simple-to-use and easy-to-understand. At the same time, we want the complicated data and AI to flow seamlessly to ensure that the data flow of information is interoperable and sent across multiple devices, making the experience seamless, functional and easy for clinicians to use.” AlderHey@nywhere™ enables the interoperability of multiple systems using FHIR, remote devices and resources for management of acute and chronic conditions. Furthermore, it collates a new unique data set for longer-term, AI-augmented decision-making for preventative intervention, personalised care and long-term disease prevention. Umang Patel, Chief Clinical Information Officer at Microsoft, also offers a unique perspective thanks to his dual role at Microsoft and as a paediatrician working in the NHS at Frimley Park Hospital. "It's been a real privilege to work with Alder Hey to develop the AlderHey@nywhere™ platform," he says. "Microsoft always loves projects that gets its staff excited - to be given the opportunity to help children and young people - was one such project. Hopefully we have been able to bring some new insights, skills and innovations that will help Alder Hey not only solve problems locally but scale beyond the Liverpool region. What they have done at Alder Hey is great for many reasons, but two stand out: first, the Alder Hey team has managed to keep it simple. If you ask 100 doctors what they want in an ideal system, they will tell you a million important things. The team has managed to scale that back, kept it usable, and brought the most important things to the front. Second, is the momentum they have generated- it's trailblazing innovation at its best.” AlderHey@nywhere™ was based around a model of prevention and intervention. The digital health platform allows for: A true hybrid of both physical and virtual patient care Remote real-time monitoring of patient care for intervention Creating a platform of care that is tailored and self-managed Digital Bio-markers and IoMT for preventive real time augmented clinical decision making Children and young people want to be empowered to engaged interactively with gamification to understand and manage their care To download our images for AlderHey @nywhere image assets available here https://we.tl/t-IYVZFHiWwj ABOUT US ABOUT ALDER HEY INNOVATION CENTRE – Todays Child, Tomorrows Healthier Adult Alder Hey Innovation is the largest, dedicated, purpose built, hospital led innovation centre in the UK. Alder Hey Children’s NHS Trust has a proud history of innovation spanning over a hundred years. Today we continue that legacy pioneering the use of cutting-edge technology and innovating to save lives and improve the life chances of today’s child. Our ambition is to be the world leader in advancing child health with innovation, utilising our unique hospital-based innovation centre, disrupting, discovering and disseminating to have real impact. Our mission is to solve the real-world healthcare problems children and young people face today, creating fair access to care and enabling a healthier future for all. Our unique strengths lie in our experience to innovate and disrupt, with a strong track record of rapid problem solving, creating an end-to-end pipeline and process from problem identification and solutions through to commercial income. Our strategy is fueled by a bespoke open innovation system, to rapidly identify real-world problems and bring the right partners together to solve those with innovative and disruptive technology. Our co creation approach involves scouting and partnering with local and international industry and academia, bringing the most innovative technology and solutions to Alder Hey, where we strive for excellence and breakthroughs in healthcare. www.alderheyinnovation.com ABOUT ALDER HEY Alder Hey Children’s NHS Foundation Trust provides care for over 330,000 children and young people every year. Alder Hey delivers clinical excellence for all children, for routine illnesses as well as very complex and rare conditions. One of four stand-alone children’s hospitals in the UK, it is a national centre for neuro and craniofacial surgery, a regional centre for burns injuries and a Centre of Excellence for children with cancer, heart, spinal and brain disease. Alder Hey as an NIHR funded Clinical Research Facility (CRF) that specialises in the design, and delivery, of early phase drug trials in children with a wide range of conditions. The Trust is one of only four epilepsy surgical centres in the UK and one of only two accredited major trauma centres in the North West. Alder Hey is also a respiratory Extracorporeal Membrane Oxygenation (ECMO) surge centre and is the referral centre for the treatment of congenital heart defects in North West England, North Wales and Isle of Man. It became the first UK Centre of Excellence for Childhood Lupus in 2010. Alder Hey is the first accredited Investing in Children hospital in the UK. It has a dedicated patient experience programme which includes the award-winning Alder Hey Arts involving music therapy, dance programmes, storytelling and animation projects. It is also one of a few hospitals to have a Children and Young Person’s Forum. Alder Hey opened a new hospital ‘Alder Hey in the Park’ in 2015. Europe’s first hospital in a park, the new facility provides a purpose-built, unique and world class healing environment for children and young people. Alder Hey is supported by The Alder Hey Children’s Charity which aims to raise vital funds for lifesaving equipment, research projects and patient experience initiatives. For more information visit www.alderhey.nhs.uk and www.alderheycharity.org ABOUT MINDWAVE Mindwave (Mindwave Ventures Limited) designs and develops digital applications for healthcare. Mindwave works with NHS organisations, charities and universities to help them develop innovative digital products to deliver healthcare and carry out health research. Mindwave's patient portal is currently deployed in over eight organisations. The company has grown to around 95 staff based in the UK and Pondicherry (South India). Mindwave's designers based in the UK are steeped in user centred design. Design and development follows Government Digital Service (GDS) guidelines and Agile principles. Born out of the NIHR Maudsley Biomedical Research Centre (BRC), Mindwave was founded in 2014; the brain-child of Kumar Jacob MBE, who trained as an accountant and then operated in different guises across a broad range of sectors, including charity, education, health and technology. Having worked with creative teams that brought out hugely popular video games such as Burnout, Singstar, WipeOut at Criterion and Sony, whilst also serving as a non-exec director at SLaM and as the chair at the Maudsley Charity, Kumar could see a disparity between the way that the public sector and the technology sector were solving problems. Enter Mindwave. Over the years, the team has grown from a handful of designers to a full-service provider, supplying expert health design and technology consultancy alongside end-to-end digital service development. To date, Mindwave has worked with a wide range of health focused organisations, including multiple NHS trusts and ICS regions, health focused charities, and a large number of clinical academic teams. Mindwave also works with and supports a number of health-tech startups, providing consultancy, design, development and project management to support peers to successfully enter the market. Mindwave is known for going above and beyond, and for the team’s eagerness to help, converse and collaborate. www.mindwaveventures.com Contact Details Alder Hey Innovation /i5 Media Gerard Franklin gerard@i5media.co.uk

June 10, 2022 02:15 AM Eastern Daylight Time

QUIDEL CORP.—DEVELOPER OF ONLY FDA-CLEARED FIA RAPID POINT-OF-CARE DIAGNOSTIC LYME DISEASE TEST—TO PARTNER WITH RENOWNED GLOBAL LYME ALLIANCE TO DRAMATICALLY HEIGHTEN LYME DISEASE AWARENESS

Quidel Corporation

With Lyme disease season in full-swing across the United States and as the public continues spending increasing time outdoors during the COVID-19 pandemic, Quidel’s recently formed Lyme Task Force Team—the only one of its kind—today announced a multitiered collaboration with Global Lyme Alliance to dramatically heighten public awareness to a health condition afflicting nearly half a million Americans each year. Quidel is the nation’s leading developer of the only rapid point-of-care diagnostic Lyme disease test. In recent years the company launched the critically acclaimed and award-winning LymeDiseaseAnswers.com website and Lyme Quick Takes online video series. “The Global Lyme Alliance has been a passionate and important partner for Quidel in our fight against Lyme disease,” said Judi Tilghman, Ph.D., vice president of technology assessment at Quidel. “Over the years they have helped fund the most urgent and promising research in the field while expanding education and awareness programs for the public and physicians. We’re honored to have this collaborative partnership.” As part of its collaboration, Quidel will serve as sponsor for GLA’s Lyme awareness month as well as a series of educational PACE-accredited webinars. These events provide new information on various Lyme topics in an open discussion format, all designed to bring awareness around the Lyme disease epidemic, with rapid ways to diagnose and treat it. In addition, Quidel will be a sponsor for the GLA Global Gala 2022, the organization’s premier fundraising event to be held in October. About Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’ s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel’ s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities, and the world. For more information about Quidel, visit quidel.com. Contact Details Jim Yeager +1 818-264-6812 jim@breakwhitelight.com Company Website http://Quidel.com

June 09, 2022 06:00 AM Pacific Daylight Time

Sylvester Feddes joins the 2022 Leading Entrepreneurs of the World Conference

1BusinessWorld

Sylvester Feddes, the Country President and Pharma Head of Novartis Colombia, joins the 2022 Leading Entrepreneurs of the World Conference to talk about leading diversity and inclusion in a virtual environment. At Novartis Colombia, Sylvester and his team use innovative science and technology to address some of society's most challenging healthcare issues by discovering and developing breakthrough treatments and finding new ways to deliver them to as many people as possible. The LEW Conference is one of the largest and most comprehensive entrepreneurial events in the world and features business presentations, digital interviews, discussions and roundtables with the world's leading entrepreneurs and business leaders. Register to attend the 2022 LEW Conference to watch the live session of Sylvester's presentation and to connect with him live at the event: https://events.zoom.us/e/view/_LwgIoXQQL2gA_LMBaozZA All news and content distribution in partnership with News Direct. About Novartis Novartis is a leading healthcare company providing solutions to the changing needs of patients. We use science-based innovation to address society's biggest health care challenges. We discover and develop advanced treatments and find new ways to ensure access to as many people as possible. Likewise, we seek to guarantee an effective return for those who invest time, resources and ideas in our company. Our goal is to improve global health. Through our business, we make an important contribution to society: we discover and develop innovative medicines. Novartis works hand in hand with others to help address some of the world's biggest health challenges. Novartis About Leading Entrepreneurs of the World As part of 1BusinessWorld, Leading Entrepreneurs of the World is one of the largest and most comprehensive entrepreneurial platforms and events in the world and features entrepreneurs, founders and business leaders presenting on cutting-edge topics and the latest industry developments. Leading Entrepreneurs of the World About 1BusinessWorld 1BusinessWorld is a global business ecosystem, network and marketplace that provides entrepreneurs, business owners and professionals with the information, tools, resources and connectivity needed to succeed throughout their company’s growth journey, toward a better business world. Our vision is based on the reality that we live, work and do business in one global interconnected business environment, and hence our motto: “One World, One Business World”. Our mission is to encourage and support global communication and collaboration among entrepreneurs, professionals, and businesses. 1BusinessWorld Contact Details 1BusinessWorld Media Enquiries +1 212-220-6677 info@1businessworld.com Company Website https://1businessworld.com

June 08, 2022 06:17 PM Eastern Daylight Time

Image

Oakland Pharmacy Inc. Partners With Comcast Business to Improve Network Management, Security and Speeds

Comcast California

Comcast Business today announced that it is providing Oakland Pharmacy Inc. – a business of community pharmacies and clinic pharmacies in Oakland, California region – with SD-WAN on the ActiveCore SM SDN Platform, Ethernet Dedicated Internet (EDI) connections for its sites as well as Business VoiceEdge® services and a 4G LTE backup connection. The combination of solutions is helping the local healthcare business improve operating procedures for its employees from the pharmacy counter to the IT desk – ultimately helping to provide elevated services for its customers. For more than 35 years, Oakland Pharmacy Inc. has served residents in Alameda County, working diligently to improve the healthcare opportunities within its communities, in particular for underserved populations – like the Asian Pacific Islander community, children incarcerated in the Juvenile Justice system, people experiencing homelessness and mental health patients – who need special healthcare assistance. Staff across the company’s seven locations are often bilingual, speaking Spanish, Cantonese, Vietnamese or Mandarin to better connect with the different cultural backgrounds that the locations serve. As medical records continue to shift to the cloud, it has become increasingly important for the pharmacy industry to have fast, reliable and secure network connections capable of quickly pulling and sending patient information. “I am very happy with the quality of service we’ve received,” said Timothy Tam, IT specialist for Oakland Pharmacy Inc. “Now our employees can more rapidly adjudicate claims, e-fax and process new prescriptions without worrying about slow network speeds.” In addition to the fast and reliable EDI connections, SD-WAN on the ActiveCore SM SDN Platform helps to configure the business’ network, as well as proactively monitor for, and troubleshoot, connectivity issues across Oakland Pharmacy Inc.’s various locations. Meanwhile, the company’s 4G LTE backup connection is helping to build network redundancy while its Business VoiceEdge® solution is providing great call quality plus a web portal to help manage calls and voicemails. “Our local pharmacies are truly the bastions of our communities. They keep us healthy, whether it’s providing vaccines, medications or other consultation on healthcare best practices,” said Kristeen Cominiello, vice president of Comcast Business in California. “Comcast Business recognizes that connectivity is the key to ensuring that these services continue to reach community members in need, and is proud to offer its support to Oakland Pharmacy Inc.” About Comcast Business Comcast Business offers a suite of Connectivity, Communications, Networking, Cybersecurity, Wireless, and Managed Solutions to help organizations of different sizes prepare for what’s next. Powered by the nation’s largest Gig-speed broadband network, and backed by 24/7 customer support, Comcast Business is the nation’s largest cable provider to small and mid-size businesses and one of the leading service providers to the Enterprise market. Comcast Business has been consistently recognized by industry analysts and associations as a leader and innovator, and one of the fastest growing providers of Ethernet services. For more information, call 866-429-3085. Follow on Twitter @ComcastBusiness and on other social media networks at http://business.comcast.com/social. About Comcast Corporation Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company that connects people to moments that matter. We are principally focused on connectivity, aggregation, and streaming with 57 million customer relationships across the United States and Europe. We deliver broadband, wireless, and video through our Xfinity, Comcast Business, and Sky brands; create, distribute, and stream leading entertainment, sports, and news through Universal Filmed Entertainment Group, Universal Studio Group, Sky Studios, the NBC and Telemundo broadcast networks, multiple cable networks, Peacock, NBCUniversal News Group, NBC Sports, Sky News, and Sky Sports; and provide memorable experiences at Universal Parks and Resorts in the United States and Asia. Visit www.comcastcorporation.com for more information. Contact Details Adriana Arvizo +1 925-200-1919 Adriana_Arvizo@comcast.com

June 08, 2022 09:05 AM Pacific Daylight Time

Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of “Immune Evasive” Cells

Kadimastem

If the feasibility study is successful, it would be a significant step forward towards pancreatic tissue engineering that could be used to develop Kadimastem’s IsletRx for diabetes in a way where transplantation would be possible without concern of immune rejection Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS, exploring other neurodegenerative diseases and developing a potential cure for diabetes, has signed an agreement with Implant Therapeutics, Inc. for use of “Immune Evasive Cell” iACT cells, (Which are implant cells that the immune system does not recognize as foreign to the body) Implant's breakthrough technology to prevent transplant rejection. Under the terms of the agreement, a feasibility study will be conducted to test if Implant Therapeutic’s iACT TM cells can provide a solution to the challenge of transplant immune protection and avoidance of rejection of Kadimastem’s IsletRx for diabetes. If so, Implant Therapeutics iACT TM cells could be a good cell source for Kadimastem to create its glucose sensing, insulin producing pancreatic cells, the basis for IsletRx, without the need of Immune protection or immunosuppression. The iACT TM “Immune Evasive” cell technology uses genetic modifications to cloak cells to be seen as part of the receiving body’s immune system and therefore are not rejected following transplantation. The success of the licensing feasibility study would be a significant step forward towards the potential to create pancreatic islet organoids, capable of producing insulin and glucagon as well as regulating blood glucose levels, that would not be rejected by the body. A successful evaluation may result in the licensing by Kadimastem of Implant Therapeutics’ technology. Kadimastem CEO Asaf Shiloni said, “This strategic agreement with Implant is the result of a long-term effort we have invested in bringing the innovative “Immune Evasive” cell technology to Kadimastem. The new capability takes us to the forefront of the race to develop diabetes care and will allow us to apply advanced technologies to create an optimal and ultimate solution to the central problem of protecting cells from the patient's own immune system. I welcome the move and hope that this technology will further advance the development of IsletRx, with the ultimate goal of improving the lives of the millions of people living with diabetes worldwide." About IsletRx IsletRx is a cell therapy treatment for diabetes, achieved by expanding the population of allogeneic stem cells differentiated into functioning insulin and glucagon producing and releasing pancreatic islet cells. The company then uses a proprietary technology to select the highest functioning cells, enrich them and then transplant them into the body. Preclinical studies have shown that the cells are able to detect the sugar levels in the body and to produce, and secrete, on demand, the required amounts of insulin and glucagon, just like a healthy pancreas. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. An INTERACT meeting took place with the FDA on October 7, 2021, where the diabetes treatment program was discussed, and the company received directions how to prepare its Pre-IND submission. About Implant Therapeutics Implant Therapeutics is a subsidiary of panCELLa whose mission is to develop therapeutic products in the immunology and cell therapy space and to partner with other companies to develop novel products in areas of regenerative medicine. Implant Therapeutics, under the guidance of Dr. Mahendra Rao, is engineering human iPSC cells that incorporate failsafe, iACT, hypoimmunogenic and safe-harbor technologies. These iPSC cells are “Immune Evasive” and are an ideal choice for replacement strategies of many cell types combining the advantages of allogeneic and autologous cells as well as allowing them to be used as ex-vivo gene therapy vehicles. To learn more, visit www.implant-rx.com. About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the Company's lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS. IsletRx is the Company's second product in development. IsletRx is comprised of functional pancreatic islet cells intended to treat patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Asaf Shiloni +972 73-797-1613 s.bazak@kadimastem.com Must Have Communications Marjie Hadad +1 917-790-1178 marjie@mhc-pr.com Company Website https://www.kadimastem.com/

June 08, 2022 07:00 AM Eastern Daylight Time

Image

Healthcare

NextFerm Technologies Announces First Commercial Production of ProteVin™, Its Vegan Protein

UK MEDTECH COMPANY TO HELP PROTECT US HEALTHCARE WORKERS AND US CITIZENS FROM 1 MILLON NEEDLESTICK INJURIES EACH YEAR

Modern Weight Loss: What is Personalized Weight Care and Why You Should Try It

All Things Bugs Achieves World First with US Patent for the use of Insects in Sustainable Food Production

ALDERHEY@NYWHERE™ CREATING A HOSPITAL OF THE FUTURE: “A HOSPITAL WITHOUT WALLS”

QUIDEL CORP.—DEVELOPER OF ONLY FDA-CLEARED FIA RAPID POINT-OF-CARE DIAGNOSTIC LYME DISEASE TEST—TO PARTNER WITH RENOWNED GLOBAL LYME ALLIANCE TO DRAMATICALLY HEIGHTEN LYME DISEASE AWARENESS

Sylvester Feddes joins the 2022 Leading Entrepreneurs of the World Conference

Oakland Pharmacy Inc. Partners With Comcast Business to Improve Network Management, Security and Speeds

Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of “Immune Evasive” Cells